Filing Flows

Filing Flows › Companies › Bio Essence › Cash flow

Bio Essence cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$60K in Q2 2026 · $1.1M over twelve months

Operating cash flow$60K
Free cash flow+$60K
Cash / net income0.2×

Analysis

In Q2 2026, Bio Essence generated $60K of operating cash flow. That is $108K less than in Q2 2025 ($168K).

Over the twelve months to Jun 30, 2026, operating cash flow was $1.1M; the largest uses were other financing ($990K); the cash balance rose by $1K.

Operating cash flow was $60K against net income of $270K — 0.2× profit, less cash than reported earnings, worth checking against working capital. The largest differences: depreciation & amortization +$104K, accrued liabilities −$12K, receivables +$5K.

Free cash flow

Bio Essence: free cash flow by quarterBio Essence: free cash flow by quarter$357KQ3 2024$423KQ4 2024−$26KQ1 2025$168KQ2 2025$187KQ3 2025$1.2MQ4 2025−$412KQ1 2026$60KQ2 2026
Operating cash flow less capital spending.
Bio Essence: operating cash flow against capital spendingBio Essence: operating cash flow against capital spendingOperating cash flowCapital spending$357K$0Q3 2024$423K$0Q4 2024−$26K$0Q1 2025$168K$0Q2 2025$187K$0Q3 2025$1.2M$0Q4 2025−$412K$0Q1 2026$60K$0Q2 2026
Latest (Q2 2026): Operating cash flow $60K, Capital spending $0.

Capital allocation, year by year

Bio Essence: where the cash came from (up) and went (down), by fiscal yearBio Essence: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingAsset salesCapital spendingAcquisitionsFY2021: Operating cash flow −$1.3MFY2021: Net borrowing $111KFY2021: Asset sales $3KFY2021: Capital spending −$119K$114KFY2021FY2022: Operating cash flow −$703KFY2022: Net borrowing −$12KFY2022: Capital spending −$4KFY2022FY2023: Operating cash flow −$1.0MFY2023: Net borrowing $1.2MFY2023: Capital spending −$4K$1.2MFY2023FY2024: Operating cash flow $624KFY2024: Net borrowing −$604KFY2024: Acquisitions −$114$624KFY2024FY2025: Operating cash flow $1.6MFY2025: Net borrowing −$385K$1.6MFY2025
Over these 5 years operating cash flow totalled −$829K; the largest uses were operating cash flow ($3.0M) and net borrowing ($1.0M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$1K
Debt$57K
Net debt$56K
Due within a year$1K

Bio Essence funds itself: free cash flow was $1.1M over the last twelve months, and $1K of cash and investments stands against $57K of debt ($1K due within a year, 0.5× covered by cash).

Bio Essence: debt maturities by year (FY2025)Bio Essence: debt maturities by year (FY2025)$1KYear 1$1KYear 2$1KYear 3$2KYear 4$2KYear 5$50KAfter year 5
Principal due in each year as disclosed in the annual report, against $1K of cash and investments now.

Where the cash came from and went

Bio Essence: sources (+) and uses (−) of cash, Q2 2026Bio Essence: sources (+) and uses (−) of cash, Q2 2026Not reconciled−$85KOperating cash flow$60KCash drawn (+) / kept (−)$36KOther financing−$10K
Bio Essence: sources (+) and uses (−) of cash, TTM to Q2 2026Bio Essence: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow$1.1MOther financing−$990KNot reconciled−$85KCash drawn (+) / kept (−)−$1K

From profit to cash

Bio Essence: net income to operating cash flow, Q2 2026Bio Essence: net income to operating cash flow, Q2 2026Net income$270KDepreciation & amortization$104KReceivables$5KPayables−$3KAccrued liabilities−$12KIncome taxes payable−$1KOperating cash flow$60K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026$60K——$36K$60K
Q1 2026−$412K$10K$440K−$36K−$412K
Q4 2025$1.2M$1.0M—$29K$1.2M
Q3 2025$187K−$375K—−$29K$187K
Q2 2025$168K−$248K——$168K
Q1 2025−$26K−$321K—$1K−$26K
Q4 2024$423K−$141K—$29K$423K
Q3 2024$357K−$310—−$20K$357K

Bio Essence: income statement and cash flow

Bio Essence, Q2 2026: revenue $795K (+207% year over year), operating margin 35.1%. The chart follows the revenue to costs, profit and cash.

Bio Essence: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.